Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

[1]  G. Lenz,et al.  Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study , 2019, American journal of hematology.

[2]  D. Scott,et al.  Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma. , 2019, Blood.

[3]  P. Barr,et al.  How I treat early-relapsing follicular lymphoma. , 2019, Blood.

[4]  Scott E. Smith,et al.  The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials , 2018, Cancer medicine.

[5]  S. Barrington,et al.  Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study , 2018, Blood.

[6]  W. Hiddemann,et al.  Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[7]  K. Tarte,et al.  An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. , 2018, Blood.

[8]  E. Kimby,et al.  Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.

[9]  F. Angrilli,et al.  Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Langer,et al.  [18F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study , 2017, Cancer.

[11]  P. Zinzani,et al.  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Salles,et al.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.

[13]  K. Foon,et al.  MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma , 2016 .

[14]  J. Cerhan,et al.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma , 2016, American journal of hematology.

[15]  G. Salles,et al.  Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Gribben,et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.

[17]  R. Davis,et al.  Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Czuczman,et al.  Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Dreyling,et al.  Abstract CT215: CHRONOS-1: Open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL) , 2015 .

[21]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[22]  M. Federico,et al.  The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  F. Angrilli,et al.  R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Houot,et al.  Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  M. Gönen,et al.  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Moreau,et al.  Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma , 2008, Haematologica.

[27]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Nazeer,et al.  Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.

[29]  U. Jaeger,et al.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Salles,et al.  Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[34]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[35]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .